Superior Glycemic Control with Taspoglutide, a Once-Weekly Human GLP-1 Analog, Compared with Twice Daily Exenatide in Type 2 Diabetes (T2DM) Inadequately Controlled on Oral Agents: The T-emerge 2 Trial

被引：0
|
作者：
Rosenstock, Julio
Balas, Bogdan
Charbonnel, Bernard
Bolli, Geremia B.
Boldrin, Mark
Ratner, Robert
Balena, Raffaella
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A17 / A17
页数：1
相关论文
共 50 条
  • [21] Weekly GLP-1 Agonist Albiglutide Monotherapy Improves Glycemic Parameters in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
    Nino, Antonio
    Okuda, Inaha
    Wilson, Timothy H.
    Yue, Lin
    Nakajima, Hiromu
    Tsuboi, Maho
    Carr, Molly C.
    DIABETES, 2016, 65 : A266 - A266
  • [22] Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial
    Henry, Robert R.
    Mudaliar, Sunder
    Kanitra, Linda
    Woloschak, Michael
    Balena, Raffaella
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (07): : 2370 - 2379
  • [23] DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
    Blevins, Thomas
    Pullman, John
    Malloy, Jaret
    Yan, Ping
    Taylor, Kristin
    Schulteis, Christine
    Trautmann, Michael
    Porter, Lisa
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05): : 1301 - 1310
  • [24] Effects of Taspoglutide on Glycemic Control and Body Weight in Obese Patients With Type 2 Diabetes (T-Emerge 7 Study)
    Hollander, Priscilla
    Lasko, Ben
    Barnett, Anthony H.
    Bengus, Monica
    Kanitra, Linda
    Pi-Sunyer, F. Xavier
    Balena, Raffaella
    OBESITY, 2013, 21 (02) : 238 - 247
  • [25] Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
    Ridge, T.
    Moretto, T.
    MacConell, L.
    Pencek, R.
    Han, J.
    Schulteis, C.
    Porter, L.
    DIABETES OBESITY & METABOLISM, 2012, 14 (12): : 1097 - 1103
  • [26] Dose-Response Improvements in Glycemic Control and Body Weight Reductions with HM11260C, a Once-Weekly GLP-1 Receptor Agonist with Liraglutide as Reference, in Type 2 Diabetes (T2DM)
    Rosenstock, Julio
    Kang, Jahoon
    Choi, Soomin
    Kim, Soojin
    Han, Oakpil
    Kil, Siyoen
    Gee, Kyuhoon
    Choi, In Young
    Kwon, Se Chang
    Trautmann, Michael
    Hompesch, Marcus
    DIABETES, 2015, 64 : A73 - A73
  • [27] Tolerability, Safety, PK/PD of Once-Weekly Administration of GLP-1 Analogue in T2DM Patients in China and US
    Liu, Ying
    Lv, Yuan
    Guo, Xiaohui
    Zhao, Caiyun
    Zhang, Junqing
    Wei, Minji
    Tracey, Gregory J.
    Lasseter, Kenneth C.
    Xu, Michael
    DIABETES, 2017, 66 : A296 - A296
  • [28] Efficacy and Safety of Once-Weekly (QW) Albiglutide vs. Once-Daily (QD) Liraglutide in Type 2 Diabetes (T2D) Inadequately Controlled on Oral Agents: Harmony 7 Trial
    Pratley, Richard E.
    Barnett, Anthony
    Feinglos, Marc M.
    Harman-Boehm, Ilana
    Nauck, Michael
    Ovalle, Fernando
    Johnson, Susan
    Stewart, Murray
    Ye, June
    Rosenstock, Julio
    DIABETES, 2012, 61 : A240 - A241
  • [29] EXENATIDE ONCE-WEEKLY (EQW) PHARMACOKINETICS AND HBA1C EXPOSURE RESPONSE ARE SIMILAR BETWEEN ADOLESCENT PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AND ADULTS WITH T2DM.
    Edlund, H.
    Melin, J.
    Penland, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S40 - S40
  • [30] Effect of Taspoglutide, a Human GLP-1 Analog, on Insulin Secretion in Patients (pts) with Type 2 Diabetes (T2D)
    Pellanda, Carolina
    Mangold, Bernhard
    Schulte, Michael
    Niggli, Markus
    Kapitza, Christoph
    DIABETES, 2010, 59 : A160 - A161
12345